NewsBenzingaWedbush mantiene su recomendación de sobreponderar sobre Denali Therapeutics y eleva el precio objetivo a 24 dólares. Wedbush mantiene su recomendación de sobreponderar sobre Denali Therapeutics y eleva el precio objetivo a 24 dólares. Benzinga 2026.11.04 14:22 (GMT+0) Open on Benzinga Other news Truist Securities Reiterates Buy on IDEAYA Biosciences, Lowers Price Target to $57 Wells Fargo Maintains Overweight on Fortune Brands, Raises Price Target to $51 Trimble Stock Sinks 18% After Q3 Sales Miss, Cut to GAAP Profit Outlook RBC Capital Maintains Outperform on Aptiv, Lowers Price Target to $64 Truist Securities Maintains Hold on Hagerty, Raises Price Target to $16 Truist Securities Reiterates Hold on Graphic Packaging Holding, Raises Price Target to $10
